Your Health Questions
Answered by Professionals

If antidepressants have not helped, this page explains why your brain may resist them and outlines new medically approved and experimental paths to care. Drivers can include inflammation, glutamate and circuit changes, genetics, or missed conditions, and next-line options include esketamine (Spravato), TMS, ECT, and in select cases VNS. There are several factors to consider: how to get access to experimental depression meds through clinical trials or expanded access, when off-label care is appropriate, what to confirm in your diagnosis, and what to document from prior trials; see the complete details below to choose the right next step with a psychiatrist.

If antidepressants have not helped, psilocybin-assisted therapy is being tested in supervised clinical trials now recruiting, and early studies suggest it can rapidly relieve symptoms for some by boosting brain connectivity and easing rigid negative patterns. There are several factors to consider. Psilocybin is not FDA-approved, not everyone responds, and there are risks plus strict eligibility and screening requirements, so talk with your doctor and see the complete details below to decide your next steps.

There are several factors to consider if depression is not improving as expected; see below to understand more about common reasons for nonresponse and about newer brain plasticity focused options like ketamine, esketamine, TMS, psychedelic assisted therapy, and anti inflammatory approaches. To qualify for a nearby clinical trial, most people need an adult diagnosis of major depression with moderate to severe symptoms and prior antidepressant attempts, then complete safety screening and informed consent, often gaining access to innovative care and close monitoring at no cost in many studies, with step by step guidance and urgent care cautions outlined below.

If you’re still depressed despite therapy, medication, or lifestyle changes, there are several factors to consider. See below to understand how slow brain chemistry shifts, chronic stress, inflammation, sleep disruption, and entrenched thought patterns can keep symptoms stuck, plus when to reevaluate treatment or seek urgent help. Clinical trials may be a next step, and many offer compensation for participating in depression research studies, including payment for time and travel, free evaluations, and access to investigational treatments, though risks and eligibility vary. For key details that could shape your next move, including advanced options and screening tools, see the complete guidance below.

Persistent depression often means your brain’s mood circuits have not rewired yet. There are several factors to consider, including misdiagnosis, treatment-resistant depression, ongoing stress, and inadequate dose or duration; see below to understand more. Evidence-based next steps include optimized or combination medications, ketamine or esketamine, TMS, ECT, targeted psychotherapies, exercise, and sleep restoration, plus urgent red flags that require immediate care; for help choosing the right plan and what to ask your doctor, see the complete details below.

There are several factors to consider; see below to understand more. Up to one third of people do not get full relief from the first antidepressant and, after two adequate trials, persistent symptoms may reflect treatment resistant depression due to medication mismatch, dose or duration issues, untreated medical or co-occurring conditions, or biology such as inflammation and brain circuit differences. Next steps can include switching or combining meds, augmentation, psychotherapy, lifestyle changes, or brain stimulation, and local clinical studies may offer new therapies with close monitoring and often no cost, with details on eligibility, working with your doctor, and when to seek urgent help outlined below.

Still feeling depressed while on medication? There are several factors to consider, including misdiagnosis or coexisting conditions, too-short or too-low-dose trials, complex brain biology beyond serotonin, and sleep or lifestyle issues; treatment resistant depression usually means no improvement after at least two adequate antidepressant trials. Evidence-based next steps include switching or combining meds, augmentation, esketamine, TMS, ECT, and adding psychotherapy plus sleep and lifestyle strategies, with urgent help needed for suicidal thoughts; see the complete guidance below to understand options and which next steps may fit your situation.

If you still feel depressed despite your medication, new evidence shows that adding a second, targeted treatment often boosts remission more than waiting longer or repeatedly switching, especially after 6 to 8 weeks of only partial benefit. Common augmentation choices include low dose atypical antipsychotics, bupropion, lithium, thyroid T3, structured psychotherapy, and addressing sleep or medical contributors, with ketamine or esketamine for some cases. There are several factors to consider, including side effects, interactions, and other diagnoses, as well as red flag symptoms that need urgent care; see below to understand more and to find next steps you can take with your clinician.

There are several factors to consider. Depression is often more than a simple serotonin issue; neurotransmitters and mood are shaped by brain circuit dysfunction, chronic stress, inflammation, and hormone or diagnostic mismatches, which is why standard therapy or SSRIs may fall short. New medical steps include personalized medication strategies (such as SNRIs or bupropion), ketamine or esketamine, TMS, targeted psychotherapy, and evidence-based lifestyle changes, but which to choose depends on your symptoms, history, and labs. See below for specific next steps, cautions, and when to seek urgent care.

If you are still depressed despite therapy, medication, and lifestyle changes, personalized, data-driven care can help, including measurement-based symptom tracking, evidence-based digital tools, targeted treatments like TMS, ECT, and ketamine or esketamine, plus integrated medical screening and trauma-informed therapies matched to your needs. There are several factors to consider. See below for the key signs you may need a new plan and the specific next steps, safety guidance, and clinician questions that can shape your best path forward.

If you are still depressed despite treatment, there are several factors to consider, including possible misdiagnosis, suboptimal medication choice or dose, unaddressed sleep or substance issues, and biological drivers like inflammation. New research-backed options such as ketamine or esketamine, TMS, and carefully combined therapies with sleep and exercise can help, and emerging psychedelic-assisted therapy is under study; the right next step depends on your specific situation, so review the complete guidance below and seek urgent help if you feel unsafe.

If your depression is not improving, there are several factors to consider, including the wrong medication fit, too-low or too-short dosing, coexisting medical or mental health conditions, and life stressors, which together can point to treatment-resistant depression after two adequate trials. See below to understand more. New FDA drug trials and treatments like esketamine, faster glutamate-targeting medicines, evidence-backed augmentation, and options such as TMS and ECT provide actionable next steps, but the best path depends on reassessing diagnosis, optimizing meds, adding therapy, and addressing safety needs, with full details and doctor-ready questions below.

If your depression is not improving on treatment, there are several factors to consider: confirm you have had an adequate dose and duration, consider switching or combining medications and adding evidence-based psychotherapy, screen for medical causes or a different diagnosis, and explore research-clinic options like TMS, ketamine or esketamine, ECT, pharmacogenomic guidance, and clinical trials. Timing matters and safety comes first, so review the 4 to 12 week response window with your clinician and seek urgent help for suicidal thoughts; key step-by-step checklists and details that could change your next move are provided below.

Zuranolone for MDD is a newer, short 14-day oral treatment that works on the brain’s GABA system rather than serotonin, so it can reduce depressive symptoms within days and may help when standard antidepressants have not. Your next steps include confirming the diagnosis, reviewing current meds and side effects, discussing candidacy, safety including driving precautions and potential costs with your clinician, and knowing when to seek urgent help, especially for suicidal thoughts or inability to care for yourself; there are several factors to consider. See below to understand more.

Chronic IBD fatigue often persists even in remission because inflammation and cytokines can impair mitochondrial energy production, while anemia, nutrient deficiencies, gut brain signaling changes, and poor sleep further drain cellular energy. Evidence based steps include testing and treating anemia, optimizing inflammation control, correcting key nutrient deficits, improving sleep, addressing mood, and gradual conditioning. There are several factors to consider, and urgent warning signs are outlined; see below for important details that could change your next steps with your healthcare provider.

Endoscopic non-healing means your gut lining still shows ulcers or inflammation on endoscopy despite treatment, which raises risks of flares, complications, and cancer in some conditions. Common reasons include inadequate medication response, low or antibody-blocked drug levels, ongoing triggers like NSAIDs or smoking, structural damage, or a missed infection or overlap condition. There are several factors to consider, and new clinical steps can help, including therapeutic drug monitoring, switching to a different mechanism, combination therapy, careful short-term steroids, targeted nutrition, and surgical consultation when needed. For practical next steps like adherence checks, trigger review, and when to seek urgent care, see the complete details below so you do not miss points that could change your care plan.

Tenesmus is the ongoing urge to pass stool even when empty, most often caused by rectal inflammation (IBD, proctitis, infections), IBS hypersensitivity, constipation, or pelvic floor dysfunction, and rarely tumors; urgent signs include rectal bleeding, black stools, weight loss, fever, severe pain, or symptoms lasting more than 2 to 3 weeks. There are several factors to consider; see below to understand more and to learn which red flags and risk factors could change your next steps. Relief is cause specific, with options that calm inflammation, optimize stool consistency, manage IBS with diet and stress strategies, add pelvic floor therapy, review medications, treat infections, and use simple comfort measures and daily habits. For a practical plan, including when to consider tests like colonoscopy and how to tailor changes safely, see the complete answer below.

Feeling emotionally numb and unmotivated often signals anhedonia, a treatable slowdown in the brain’s dopamine-based reward circuits, which is why typical serotonin-focused antidepressants may leave these symptoms behind. There are several evidence-based options to consider, including dopamine-targeting medication adjustments like bupropion and newer options such as esketamine or ketamine, targeted therapies like behavioral activation or CBT, brain stimulation like TMS or ECT, and supportive steps with sleep, exercise, nutrition, and small social contacts; seek urgent help for self-harm thoughts. For the full list, decision points, and how to choose next steps with your clinician, see below.

There are several factors to consider: ongoing flares can result from a mismatch between your medication and biology, smoldering inflammation that symptoms miss, too low drug levels, or non inflammatory look-alikes like IBS or infection; objective tests such as fecal calprotectin and therapeutic drug monitoring help pinpoint the cause. See below for key details that could change your next steps. New remote monitoring IBD trials use app based symptom tracking, at home stool tests, medication level optimization, and virtual specialist access to detect inflammation early, adjust therapy faster, reduce hospitalizations, and support switching among multiple drug classes when needed; seek urgent care for severe pain, high fever, heavy bleeding, or rapid weight loss.

If you are still flaring on Skyrizi, there are several factors to consider; see below to understand more. Likely causes include primary non-response, secondary loss of response from low drug levels or antibodies, mechanical complications, or a different condition, and next steps usually include targeted blood and stool tests, optimizing Skyrizi or brief steroids, switching to another biologic or a JAK inhibitor, and addressing complications, with urgent red flags and decision guidance outlined below.

IBD research studies now point to a proactive, personalized path to remission that goes beyond symptom relief, targeting deep healing through treat-to-target monitoring, advanced biologics and small-molecule drugs, and emerging precision medicine and microbiome approaches. If you are still flaring, there are several factors to consider, from hidden inflammation and drug antibodies to diet, lifestyle, and clinical trial options; see below for key warning signs, when to reassess with your GI, and practical next steps that could change your care plan.

There are several factors to consider if your ulcerative colitis keeps flaring: new diet-based trials show plans like the Mediterranean and other anti-inflammatory diets can ease symptoms and may support remission, but they cannot replace effective medicines such as 5-ASA, biologics, or JAK inhibitors. The most important next steps are to confirm true inflammation, check adherence and infections, optimize or escalate therapy, and use supervised diet adjustments for symptom relief, with urgent care for red flags like heavy bleeding or fever; see the complete, practical guidance below, as key details there can shape your next decisions.

New IBD medications in 2026 expand options for people still flaring, including next generation IL-23 inhibitors and new oral therapies like selective JAK inhibitors and S1P modulators, alongside more personalized, data-driven care aimed at deeper remission and mucosal healing. There are several factors to consider, including safety tradeoffs, monitoring, and clear signs it may be time to switch. See below for who benefits most, key differences between drugs, combination strategies, lifestyle and surgery considerations, and step-by-step next actions to take with your gastroenterologist that could change your care plan.

New head-to-head data show Skyrizi generally achieves higher endoscopic remission than Stelara, with similar or slightly higher clinical remission and comparable safety, especially after anti-TNF failure. There are several factors to consider; see below for the exact remission rates, durability, who tends to benefit from each, dosing logistics, safety nuances, and red flags that should guide your next steps with a gastroenterologist.

If you are still flaring with IBD despite treatment, AI-guided drug discovery is uncovering new inflammatory targets, predicting who will respond to specific therapies, and speeding safer, more precise options into trials and care. There are several factors to consider, from reassessing your diagnosis and inflammation markers to exploring optimized regimens and clinical trials, plus urgent warning signs and timelines to set expectations; see below for the complete answer with the details that can shape your next medical steps.

Clinical trial patient stipends for IBD reduce costs like travel, parking, childcare, and time off, making it easier to join studies that may offer access to innovative treatments and high level monitoring you might not get in routine care. There are several factors to consider, including eligibility, potential side effects or placebo, visit commitments, taxes on stipends, and how trials coordinate with your current doctor; see below for the full details that could shape your next steps and when to seek urgent care.

If you are still flaring with IBD despite treatment, medically regulated clinical trials can be the next step, offering access to new targeted therapies, close specialist monitoring, and often no-cost study care, and they are not a last resort. Whether a trial fits your situation depends on disease severity, past response or intolerance to medicines, eligibility and safety details such as placebo use and rescue plans, and knowing when symptoms need urgent care, so review the full guidance below to decide the right next steps with your doctor.

If you're still flaring with mild to moderate UC, new research studies may be a vital next step, offering access to targeted therapies and close monitoring that pursue symptom remission, endoscopic healing, less steroid use, and prevention of long-term complications. There are several factors to consider, including who should consider trials, safety oversight and placebo use, and practical steps to discuss with your gastroenterologist; see below for important details that could influence your next care decisions.

There are several factors to consider. Nutritional therapy trials for Crohn’s disease can be a smart next step when you are still flaring despite medication, complementing your current treatment with supervised, evidence-based diets like exclusive or partial enteral nutrition, the Crohn’s Disease Exclusion Diet, and other anti inflammatory approaches to reduce inflammation, support gut healing, improve quality of life, and sometimes reduce steroid dependence. See below for key details that could shape your next steps, including who is most likely to benefit, what the research shows, safety and monitoring, how to find trials, questions to ask your doctor, and which red flag symptoms need urgent care.

Still flaring on ulcerative colitis treatment? New oral clinical trials may be your next step, offering access to targeted pills being studied, including JAK inhibitors, S1P modulators, and TYK2 inhibitors, with close specialist monitoring, though benefits, risks, and eligibility vary and should be reviewed with your gastroenterologist. There are several factors to consider. See below for how to confirm active inflammation, what the trial process and costs involve, potential side effects and safety safeguards, and the urgent red flag symptoms so you can choose the right next step for your care.